HDAC9 and neoplasm: Despite the fact that research has mainly focused on the effects of HDAC inhibitors on neoplastic cells, recent data support their potential to regulate the anti-tumor immune response via epigenetic modification, as well as their impact on the mechanisms mediating the effects of other anti-cancer therapies [21].